But again, that really doesn't mean much if you don't also get a p value <.05 does it? And it doesn't seem like we have any way of knowing the p value given the data we have so far. Are there instances where hazard ratios still matter even if p value >.05?
By itself I agree that any total trial p value >0.05 means that the trial was a "failure" (albeit for a ph ii the p value requirement is less).
However - I am combining this with the apriori data from other chemos that says that the HR during the early part of the curve is more indicative of chemo efficacy than the latter part of the curve. So I look at a stellar p value in the early part of the curve is strongly indicative of efficacy even if later the p value decreases.
Market Data 
Markets 
AI
